Skip to main content

Page last checked

Research compound · not FDA-approved

MariTide

Also called maridebart cafraglutide or AMG 133.

MariTide is the short name for maridebart cafraglutide, an experimental shot for weight management.

What matters first

Why people look it up
Researchers are studying MariTide for weight management.
What the evidence shows
A Phase 2 trial reported average weight loss in groups with and without type 2 diabetes. Two Phase 3 studies are active but have no results.
Dose status
MariTide is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Evidence snapshot

Published human trial

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study1 reported dose row
Safety evidence
No listed safety findingsNo reactions reported here
Sources
6 cited sourcesMedical review complete · 2026-09-07
Open the shareable evidence image
MariTide at a glance: published human trial, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how it works · how good the evidence is · questions

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about MariTide

MariTide is the short name for maridebart cafraglutide, an experimental shot for weight management. It activates GLP-1 receptors and blocks GIP receptors. In a 592-person Phase 2 trial, average weight change after 52 weeks was a loss of 12.3% to 16.2% across study groups without type 2 diabetes, compared with 2.5% with placebo. In study groups with type 2 diabetes, the range was 8.4% to 12.3%, compared with 1.7% with placebo. Two Phase 3 studies are active but have no results.

MariTide research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourceHuman trial
FDA approvalNot FDA-approved
Studied dosing140–420 mg every four weeks in most Phase 2 groups; one 420 mg group received it every eight weeks, and two groups increased doses gradually — from clinical trials
PresentationMariTide has no approved vial or mixing instructions; its studies use prepared subcutaneous injections.

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

How MariTide works

MariTide acts at GIP + GLP-1. Here is what that means.

A dual agonist switches on the receptors for both hormones your gut releases after eating: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both were first understood as insulin boosters, and combining them started out as a diabetes idea. The weight loss that followed was bigger than the GLP-1 half alone would explain, and researchers still do not agree on why.

◆ Receptor targets2 of 4 · GIP + GLP-1
4What each receptor does — 4 rows in the data table
Receptors targeted by MariTide, and what each receptor does
ReceptorMariTideWhat it does
GLP-1targetedInsulin release while blood sugar is rising, less glucagon, slower stomach emptying, and less appetite — the same physiology a single-target drug produces, carried here by the same molecule.
GIPtargetedpancreatic isletGIP is the other gut hormone, released higher up the small intestine. It boosts insulin alongside GLP-1, which is why the two together move blood sugar more than either does alone.adipose tissue and brainGIP receptors also sit on fat cells. There, the hormone has a hand in how nutrients get stored and how blood moves through fat tissue. These receptors also sit in the brain regions handling appetite and nausea. What GIP actually contributes to weight loss is disputed — blocking the same receptor has also produced benefit in experiments.
Glucagonnot targeted—
Amylinnot targeted—

The same four receptor groups are shown for every drug, so the differences are easy to compare. Targets come from the drug class. Any result specific to MariTide comes from the cited sources.

The honest summary: the two-receptor design has beaten single-target GLP-1 in trials, and the explanation is unfinished. One leading idea is that GIP signaling in the brain dampens the nausea that limits GLP-1 dosing. In that hypothesis, a dual agonist can be pushed further before side effects stop it. That is a hypothesis, not a finding — any confident story about what GIP does is running ahead of the evidence.

What the evidence for MariTide is

These numbers come from a study in people that was published in a peer-reviewed journal. The drug or dose may still be experimental and may not have FDA approval.

Human trial
What it establishes
The study gave known doses to a defined group, monitored what happened and compared the results with another group.
What it does not establish
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Read each result with the study length, dose and number of participants. Results from separate trials are not a direct comparison because the people and study designs differ.

Where MariTide is in clinical trials

27 registered studies; the program has reached phase 3, and 8 are still enrolling.

The soonest a running study expects to finish measuring people is November 2026. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.

  • Phase 3Recruiting

    Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    Amgen · Obesity, Overweight · 950 participants planned · started July 2026

    Main measurement due December 2027 (sponsor estimate)

    NCT07684144 on ClinicalTrials.gov

  • Phase 3Recruiting

    Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    Amgen · Obesity, Overweight · 3,200 participants planned · started July 2026

    Main measurement due December 2027 (sponsor estimate)

    NCT07684235 on ClinicalTrials.gov

  • Phase 3Recruiting

    Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

    Amgen · Obesity or Overweight · 300 participants planned · started May 2026

    Main measurement due January 2028 (sponsor estimate)

    NCT07575399 on ClinicalTrials.gov

Searched under the name maridebart cafraglutide, which is how the registry files it.

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-07

Every compound we track, and what stage each one has reached →

Regulatory status

MariTide is investigational and has no FDA-approved product or prescribing schedule.

The amounts below belong to monitored Phase 2 study groups. They are not instructions for personal use or a forecast of one person’s result.

Full regulatory tracker →

Where to go next on MariTide

Vial, water and dose for any peptide, with MariTide as one example

U-100, U-50 and U-40 barrels each read differently, including MariTide

Petrelintide on its own page, separate from MariTide

Petrelintide has published human trial data, separate from MariTide.

The source-checked survodutide entry, beyond the MariTide one

No regulator has approved survodutide — beyond MariTide.

The source-checked pemvidutide entry, beyond the MariTide one

No regulator has approved pemvidutide — beyond MariTide.

What the mazdutide page carries, separate from MariTide

6 sourced mazdutide reactions, on its own page, separate from MariTide.

What the zenagamtide page carries, separate from MariTide

2 sourced zenagamtide reactions, on its own page, separate from MariTide.

What the retatrutide page carries, separate from MariTide

6 sourced retatrutide reactions, on its own page, separate from MariTide.

The source-checked eloralintide entry, beyond the MariTide one

No regulator has approved eloralintide — beyond MariTide.

Cagrilintide on its own page, separate from MariTide

Cagrilintide has published human trial data, separate from MariTide.

Liraglutide in the full list, alongside MariTide

Half-life 13 hours for liraglutide, cited apart from MariTide.

Safety notes

  • Investigational compound — no FDA-approved product or prescribing schedule exists
  • Gastrointestinal side effects were common in Phase 2, but the published abstract gives no exact rates
  • The two active Phase 3 studies have no results

Questions about MariTide

Is MariTide FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is MariTide taken?

By injection under the skin, every four weeks in most Phase 2 groups.

How does MariTide differ from the other compounds in this class?

It acts at GIP + GLP-1. Adding or removing a receptor changes the effect. It also changes how much people can tolerate. These molecules are not swappable at the same number of milligrams. Comparing them milligram for milligram is the most common mistake in this category.

The nearest alternatives act elsewhere:

  • Semaglutide (GLP-1 alone)
  • Liraglutide (GLP-1 alone)
  • Retatrutide (GIP + GLP-1 + glucagon)
  • Cagrilintide (amylin)
  • Survodutide (glucagon + GLP-1)
  • Mazdutide (glucagon + GLP-1)
  • Zenagamtide (GLP-1 + amylin)
  • Pemvidutide (glucagon + GLP-1)
  • Eloralintide (amylin)
  • Petrelintide (amylin)

What is not known about MariTide?

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

6primary sources, each with the day we read it — open the documents used on this page